Company Encyclopedia
View More
name
SPRUCE BIOSCIENCES INC
SPRBD.US
1.902 T
SPRBD.USMarket value -Rank by Market Cap -/-

Financial Score

14/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking350/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-133.62%E
    • Profit Margin-3721.17%E
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-86.43%E
    • Net Profit YoY-12.13%D
    • Total Assets YoY-71.11%E
    • Net Assets YoY-77.72%E
  • Cash ScoreE
    • Cash Flow Margin-2.69%D
    • OCF YoY-86.43%E
  • Operating ScoreE
    • Turnover0.03E
  • Debt ScoreB
    • Gearing Ratio39.60%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Pres Gharib Acquires 1,550 Of Spruce Biosciences Inc [SPRB]

    Gharib Samir M, President of Spruce Biosciences Inc, filed a Form 4 with the SEC, disclosing changes in ownership. He acquired 1,550 shares, exercised 2,414 shares, and surrendered 864 shares to cover option exercise costs and tax liabilities. His ending holdings are 7,616 shares directly. This event highlights insider trading activities within the company.

    Reuters·
    US
    SPRBD
    0.00%
    US
    SPRB
    -5.67%
    US
    SPRBX
    0.00%
    Reuters·
    US
    SPRBD
    0.00%
    US
    SPRB
    -5.67%
    US
    SPRBX
    0.00%

    CEO Szwarcberg Acquires 3,524 Of Spruce Biosciences Inc [SPRB]

    CEO Javier B Szwarcberg of Spruce Biosciences Inc acquired 3,524 shares, as disclosed in a Form 4 filed with the SEC on December 12, 2025. The transaction involved exercising 6,146 shares and surrendering 2,622 shares to cover option exercise costs and tax liabilities, resulting in direct holdings of 12,998 shares.

    Reuters·
    US
    SPRB
    -5.67%
    US
    SPRBX
    0.00%
    US
    SPRBD
    0.00%
    Reuters·
    US
    SPRB
    -5.67%
    US
    SPRBX
    0.00%
    US
    SPRBD
    0.00%

    Spruce Biosciences Announces Board Resignation and Stock Repricing

    Spruce Biosciences announced the resignation of Tiba Aynechi, Ph.D. from its board and a stock option repricing to $104.13 per share to retain employees. The latest analyst rating is a Buy with a $160.00 target, but TipRanks' AI Analyst rates it as Underperform due to financial challenges. The company faces declining revenues and losses, despite potential growth from a strategic acquisition. Current market cap is $91.7M.

    Tip Ranks·
    US
    SPRBD
    0.00%
    US
    SPRB
    -5.67%
    Tip Ranks·
    US
    SPRBD
    0.00%
    US
    SPRB
    -5.67%

    Spruce Biosciences Reprices Stock Options to Boost Employee Retention

    Spruce Biosciences Inc. has approved a stock option repricing plan effective December 11, 2025, reducing exercise prices to market value. Options become exercisable after a retention period or upon FDA approval of tralesinidase alfa or a change in control. CEO Javier Szwarcberg and CFO Samir Gharib are among those affected. This move aims to boost employee retention.

    Reuters·
    US
    SPRB
    -5.67%
    US
    SPRBD
    0.00%
    Reuters·
    US
    SPRB
    -5.67%
    US
    SPRBD
    0.00%

    Spruce Biosciences Completes One-for-75 Reverse Stock Split

    Spruce Biosciences Inc. has completed a one-for-75 reverse stock split and resumed trading on the Nasdaq Capital Market under the ticker symbol "SPRB" as of September 2025. This announcement was originally published via Business Wire on November 10, 2025.

    Reuters·
    US
    SPRB
    -5.67%
    Reuters·
    US
    SPRB
    -5.67%
    © 2025 Longbridge｜Disclaimer